SG10201505218YA - Factor ix polypeptides and methods of use thereof - Google Patents

Factor ix polypeptides and methods of use thereof

Info

Publication number
SG10201505218YA
SG10201505218YA SG10201505218YA SG10201505218YA SG10201505218YA SG 10201505218Y A SG10201505218Y A SG 10201505218YA SG 10201505218Y A SG10201505218Y A SG 10201505218YA SG 10201505218Y A SG10201505218Y A SG 10201505218YA SG 10201505218Y A SG10201505218Y A SG 10201505218YA
Authority
SG
Singapore
Prior art keywords
polypeptides
factor
methods
Prior art date
Application number
SG10201505218YA
Other languages
English (en)
Inventor
Glenn Pierce
Samantha Truex
Robert T Peters
Haiyan Jiang
Original Assignee
Biogen Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201505218Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Hemophilia Inc filed Critical Biogen Hemophilia Inc
Publication of SG10201505218YA publication Critical patent/SG10201505218YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201505218YA 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof SG10201505218YA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36306410P 2010-07-09 2010-07-09
US201061424555P 2010-12-17 2010-12-17
US201161430819P 2011-01-07 2011-01-07
US201161438572P 2011-02-01 2011-02-01
US201161442079P 2011-02-11 2011-02-11
US201161470951P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
SG10201505218YA true SG10201505218YA (en) 2015-08-28

Family

ID=45441870

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201505218YA SG10201505218YA (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof
SG2012096053A SG186856A1 (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof
SG10201913700SA SG10201913700SA (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2012096053A SG186856A1 (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof
SG10201913700SA SG10201913700SA (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof

Country Status (24)

Country Link
US (13) US9670475B2 (cg-RX-API-DMAC7.html)
EP (3) EP2590668A4 (cg-RX-API-DMAC7.html)
JP (5) JP2013534426A (cg-RX-API-DMAC7.html)
KR (5) KR20230156435A (cg-RX-API-DMAC7.html)
CN (1) CN103140237A (cg-RX-API-DMAC7.html)
AU (5) AU2011274414B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013000650A8 (cg-RX-API-DMAC7.html)
CA (1) CA2804274A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000058A1 (cg-RX-API-DMAC7.html)
DK (1) DK3552619T3 (cg-RX-API-DMAC7.html)
EA (2) EA028067B1 (cg-RX-API-DMAC7.html)
ES (1) ES3050283T3 (cg-RX-API-DMAC7.html)
FI (1) FI3552619T3 (cg-RX-API-DMAC7.html)
IL (3) IL223990B (cg-RX-API-DMAC7.html)
LT (1) LT3552619T (cg-RX-API-DMAC7.html)
MX (3) MX375112B (cg-RX-API-DMAC7.html)
MY (2) MY166954A (cg-RX-API-DMAC7.html)
NZ (1) NZ605348A (cg-RX-API-DMAC7.html)
PL (1) PL3552619T3 (cg-RX-API-DMAC7.html)
PT (1) PT3552619T (cg-RX-API-DMAC7.html)
RS (1) RS67366B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201505218YA (cg-RX-API-DMAC7.html)
UA (2) UA126265C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012006624A2 (cg-RX-API-DMAC7.html)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CA2863329C (en) 2012-01-12 2023-01-03 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
EP2814840B1 (en) 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
HK1212882A1 (zh) 2012-07-25 2016-06-24 Bioverativ Therapeutics Inc. 血液因子的監測分析及其用途
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
SI2956477T2 (sl) 2013-02-15 2024-05-31 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EA037906B1 (ru) * 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US20160346366A1 (en) * 2013-12-23 2016-12-01 Csl Limited Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2017024060A1 (en) * 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
PL3442656T3 (pl) 2016-04-15 2024-04-29 Takeda Pharmaceutical Company Limited Sposób i aparat do zapewniania farmakokinetycznego schematu dawkowania leku
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
PL3481416T3 (pl) 2016-07-08 2021-03-22 CSL Behring Lengnau AG Podskórne podawanie długo działającego czynnika ix u ludzi
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
TW201831521A (zh) 2017-01-31 2018-09-01 美商生物化學醫療公司 因子ｉｘ融合蛋白以及其製備方法及使用方法
US11185245B2 (en) 2017-06-03 2021-11-30 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure for muscle compartment syndrome
US10813589B2 (en) 2017-06-03 2020-10-27 Sentinel Medical Technologies, LLC Catheter for monitoring uterine contraction pressure
US10799131B2 (en) 2017-06-03 2020-10-13 Sentinel Medical Technologies, LLC Catheter for monitoring intrauterine pressure to protect the fallopian tubes
US11045128B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter for monitoring intra-abdominal pressure
US11045143B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter with connectable hub for monitoring pressure
KR102597725B1 (ko) 2017-06-29 2023-11-06 체에스엘 베링 렝나우 아게 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법
KR102780287B1 (ko) 2017-08-09 2025-03-14 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US11672457B2 (en) 2018-11-24 2023-06-13 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11779263B2 (en) 2019-02-08 2023-10-10 Sentinel Medical Technologies, Llc. Catheter for monitoring intra-abdominal pressure for assessing preeclampsia
KR20210141608A (ko) 2019-03-19 2021-11-23 체에스엘 베링 렝나우 아게 치료요법에서 인자 ix 변이체 및 이의 용도
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
US11730385B2 (en) 2019-08-08 2023-08-22 Sentinel Medical Technologies, LLC Cable for use with pressure monitoring catheters
JP2022549932A (ja) 2019-09-30 2022-11-29 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
US11617543B2 (en) 2019-12-30 2023-04-04 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
EP4362971A1 (en) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件
JP2025534659A (ja) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド 疾患治療のための改変細胞及び移植可能エレメント

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
AU666388B2 (en) 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
ATE203274T1 (de) 1994-02-01 2001-08-15 Nasa Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
DK0805628T3 (da) 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specifik transepitheltransport af immunogener
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2001522230A (ja) * 1997-02-14 2001-11-13 アメリカン・レツド・クロス トランスジェニック動物乳房組織における活性ヒト第▲ｉｘ▼因子の発現
BR9815975A (pt) 1998-07-31 2001-12-04 Wallace E Carroll Método e aparelho para a determinação defatores de terapia anticoagulante
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2418748A1 (en) 2000-04-28 2001-11-08 Inflazyme Pharmaceuticals Limited 3-nitrogen-6,7-dioxygen steroids and uses related thereto
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
KR20040039328A (ko) 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 변형된 펙터 ⅸ
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
CN1761747A (zh) * 2003-03-18 2006-04-19 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
EP1617799A2 (en) 2003-04-09 2006-01-25 Wyeth Hemophilia treatment by inhalation of coagulation factors
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US7212798B1 (en) * 2003-07-17 2007-05-01 Cisco Technology, Inc. Adaptive AGC in a wireless network receiver
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
BRPI0417341A (pt) 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
US8828939B2 (en) 2004-08-17 2014-09-09 Csl Behring Gmbh Modified vitamin K dependent polypeptides
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
US20060162552A1 (en) 2005-01-26 2006-07-27 Mohawk Valley Energy Solutions, Inc. Systems and methods for controlling room air quality
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP3593790A1 (en) 2005-11-01 2020-01-15 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
ES2987558T3 (es) 2006-03-24 2024-11-15 Bioverativ Therapeutics Inc PC5 como enzima de procesamiento de propéptido de factor IX
JP2009533364A (ja) * 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法
CA2653154A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101641899B1 (ko) * 2006-06-14 2016-08-01 체에스엘 베링 게엠베하 혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
EP2046371A2 (en) 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Factor viia analogues with increased activity for treating thrombocytopenia
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
EP2209487A4 (en) 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
EP2288622A4 (en) 2008-04-16 2012-04-18 Bayer Healthcare Llc FACTOR IX MODIFIED POLYPEPTIDES AND USES THEREOF
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
US20090282865A1 (en) 2008-05-16 2009-11-19 Ortloff Engineers, Ltd. Liquefied Natural Gas and Hydrocarbon Gas Processing
BRPI0917656A2 (pt) * 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
KR20110079670A (ko) 2008-09-24 2011-07-07 스타빌리테크 리미티드 슈가 및 폴리에틸렌이민을 사용하여 폴리펩티드를 보존하는 방법
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
WO2011030641A1 (ja) 2009-09-08 2011-03-17 コニカミノルタホールディングス株式会社 身体用装具
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3542861A1 (en) 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
DK2956002T3 (en) 2013-02-16 2017-12-11 Albumedix As Pharmacokinetic animal model
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
US20160346366A1 (en) 2013-12-23 2016-12-01 Csl Limited Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

Also Published As

Publication number Publication date
US9670475B2 (en) 2017-06-06
US9675676B2 (en) 2017-06-13
UA126265C2 (uk) 2022-09-14
IL277432A (en) 2020-11-30
JP2022044828A (ja) 2022-03-17
PL3552619T3 (pl) 2025-12-01
AU2017268650B2 (en) 2019-10-10
SG186856A1 (en) 2013-02-28
US20160166657A1 (en) 2016-06-16
KR20230156435A (ko) 2023-11-14
UA115120C2 (uk) 2017-09-25
MX2020009702A (es) 2020-10-07
CA2804274A1 (en) 2012-01-12
US9867873B2 (en) 2018-01-16
KR20180118808A (ko) 2018-10-31
US20180228879A1 (en) 2018-08-16
US10561714B2 (en) 2020-02-18
FI3552619T3 (fi) 2025-11-05
MY192639A (en) 2022-08-29
WO2012006624A3 (en) 2012-08-02
IL277432B (en) 2021-07-29
US20210023185A1 (en) 2021-01-28
LT3552619T (lt) 2025-11-10
US20160346365A1 (en) 2016-12-01
US9629903B2 (en) 2017-04-25
RS67366B1 (sr) 2025-11-28
ES3050283T3 (en) 2025-12-19
EP3552619A1 (en) 2019-10-16
AU2020200118A1 (en) 2020-01-30
EP3552619B1 (en) 2025-07-30
JP2019023242A (ja) 2019-02-14
MX2013000281A (es) 2013-03-22
WO2012006624A2 (en) 2012-01-12
US20160243206A1 (en) 2016-08-25
AU2022204643B2 (en) 2025-08-28
AU2017268650A1 (en) 2017-12-21
JP2017036328A (ja) 2017-02-16
US10568943B2 (en) 2020-02-25
KR20140017480A (ko) 2014-02-11
AU2011274414B2 (en) 2016-10-06
EP2590668A4 (en) 2014-04-02
MY166954A (en) 2018-07-25
AU2020200118B2 (en) 2022-04-07
PT3552619T (pt) 2025-10-23
CL2013000058A1 (es) 2014-03-28
AU2022204643A1 (en) 2022-07-21
BR112013000650A2 (pt) 2016-05-31
JP2013534426A (ja) 2013-09-05
US20160257943A1 (en) 2016-09-08
US20190192641A1 (en) 2019-06-27
JP2016034973A (ja) 2016-03-17
US20180207244A1 (en) 2018-07-26
IL223990B (en) 2020-10-29
US10548954B2 (en) 2020-02-04
IL284368A (en) 2021-07-29
MX356527B (es) 2018-06-01
AU2016228243A1 (en) 2016-10-06
KR20190104442A (ko) 2019-09-09
EA037095B1 (ru) 2021-02-05
US20130171175A1 (en) 2013-07-04
DK3552619T3 (da) 2025-10-20
MX375112B (es) 2025-03-06
CN103140237A (zh) 2013-06-05
NZ605348A (en) 2015-01-30
EA201291480A1 (ru) 2013-09-30
US20180228878A1 (en) 2018-08-16
US20130202595A1 (en) 2013-08-08
US10898554B1 (en) 2021-01-26
US9623091B2 (en) 2017-04-18
AU2011274414A1 (en) 2013-01-24
US9233145B2 (en) 2016-01-12
EA028067B1 (ru) 2017-10-31
KR20220097518A (ko) 2022-07-07
EA201790876A1 (ru) 2017-12-29
BR112013000650A8 (pt) 2017-10-17
EP2590668A2 (en) 2013-05-15
EP4653528A2 (en) 2025-11-26
US20210008178A1 (en) 2021-01-14
SG10201913700SA (en) 2020-03-30
AU2016228243B2 (en) 2017-08-31
US20190192640A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
IL284368A (en) Factor ix polypeptides and methods of using them
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
EP2791333A4 (en) OPSINE POLYPEPTIDES AND METHODS OF USE
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL247595A0 (en) New modulators and methods of use
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
LT2539326T (lt) Sujungti bisariliniai ariltriazolonai ir jų panaudojimas
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
ZA201209205B (en) Pyridone and aza-pyridone compounds and methods of use
IL222027A (en) Peptides and their use
SG10201601792UA (en) Novel modulators and methods of use
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
IL222900A0 (en) New forms of rifaximin and uses thereof
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
WO2011140391A9 (en) Egfr-related polypeptides and methods of use
SG173752A1 (en) Modifications of cupredoxin derived peptides and methods of use thereof
IL222714A0 (en) Preparation of polypeptides and salts thereof
EP2611459A4 (en) POLYPEPTIDES DERIVED FROM ALPHA-1-ANTITRYPSIN AND METHOD FOR THEIR USE
PL2558485T3 (pl) Antygeny polipeptydowe z trichinella i ich zastosowania
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB201015385D0 (en) Socket cover and method of use thereof